CIBC Bancorp USA’s Spyre Therapeutics SYRE Stock Holding History
Bought
Maintained
Sold
Other funds holding SYRE
CIBC Bancorp USA's SYRE Position: Q3 2026 in Review
CIBC Bancorp USA increased its Spyre Therapeutics (SYRE) stake by 97% in Q3 2026, buying an estimated $384K and bringing the position to 8,118 shares worth $723K. The position accounts for ﹤0.01% of the portfolio, ranked #1199.
CIBC Bancorp USA first reported a position in SYRE in Q2 2026 and has held it in 2 quarters since. 286 funds tracked by Wall St. Rank hold SYRE as of Q3 2026.
- CIBC Bancorp USA held 8,118 shares of Spyre Therapeutics worth $723K as of Q3 2026.
- CIBC Bancorp USA bought 3,996 Spyre Therapeutics shares in Q3 2026, an estimated $384K.
- Spyre Therapeutics made up ﹤0.01% of CIBC Bancorp USA's portfolio in Q3 2026, its #1199 holding.
- CIBC Bancorp USA first reported a position in Spyre Therapeutics in Q2 2026 and has held it in 2 quarters since.
- 286 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2026.
Based on CIBC Bancorp USA's 13F filing for Q3 2026, filed 13 Nov 2026.